Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subarachnoid hemorrhage (SAH) is a devastating acute brain injury due to bleeding onto the brain surface from a ruptured aneurysm. Cerebral vasospasm (cVSP; critical narrowing of brain arteries) is a known complication after SAH and significantly increases disability and death after SAH. Vasospasm is difficult to treat and can lead to stroke. Animal studies have shown that the muscles in the artery wall play a role in cVSP.

Dantrolene has been FDA approved and extensively used in clinical practice as a muscle relaxant for more than 30 years. It has been shown to provide some benefit in animal studies of cVSP, as well as in a small number of humans. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with dantrolene in patients with cVSP after SAH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with Dantrolene can improve the outcome of patients with cVSP after SAH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Dantrolene in Subarachnoid Hemorrhage

NCT01024972

Subarachnoid Hemorrhage Cerebral Vasospasm

COMPLETED PHASE1/PHASE2

Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

NCT00930072

Vasospasm

TERMINATED PHASE2

Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm

NCT03517670

Cerebral Vasospasm Subarachnoid Hemorrhage

COMPLETED

Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)

NCT00796900

Hyperthermia

TERMINATED PHASE2/PHASE3

Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage

NCT04362527

Vasospasm

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of dantrolene, by determining the treatment related adverse events, in participants with cVSP after SAH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies and 3) to determine efficacy trends of dantrolene on brain vessels as assessed by ultrasound of brain vessels (transcranial Doppler).

We hypothesize that dantrolene is well-tolerated and has minimal serious adverse effects in patients with cVSP after SAH. The results can potentially bring a new treatment to patients with SAH. cVPS after SAH is a frequent cause of disability and death. A successful study demonstrating the safety of dantrolene in would be of considerable public health significance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Vasospasm After Subarachnoid Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dantrolene (low dose)

Group Type EXPERIMENTAL

Dantrolene

Intervention Type DRUG

1.25 mg/kg IV once over 60 min

Dantrolene (high dose)

Group Type EXPERIMENTAL

Dantrolene

Intervention Type DRUG

2.5 mg/kg IV once over 60 min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dantrolene

1.25 mg/kg IV once over 60 min

Intervention Type DRUG

Dantrolene

2.5 mg/kg IV once over 60 min

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with aneurysmal SAH admitted to the Massachusetts General Hospital NeuroICU (Blake 12) and undergoing standard-of-care daily transcranial doppler (TCD).
* Participants with unilateral or bilateral anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA), or basilar artery vasospasm as defined by the following TCD criteria
* a \>50% mean velocity increase from the baseline mean TCD velocity (baseline is the first TCD measurement, usually within 24hrs of admission), or
* peak systolic TCD velocities of 200 cm/s or higher in the MCA or ACA (for MCA with a concurrent ipsilateral LR of 3.0 or higher), or peak systolic TCD velocities of 120 cm/s or higher in the PCA or basilar artery, or
* any daily 100 cm/s peak systolic TCD velocity increase from the previous day, or
* any longitudinal mean TCD velocity increase of 80 cm/s or more

Exclusion Criteria

* Inability to obtain consent from patient or health care proxy
* Age \< 18 years
* Pregnancy
* Traumatic SAH
* Known allergy to dantrolene
* Prior history of cirrhosis or hepatitis B/C, or any two of the following three liver enzymes elevated to greater than: ALT \>165 Units/L, AST \>120 Units/L, alkaline phosphatase \>345 Units/L (three times upper limit of normal)
* Participants on verapamil

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No